Ries M - Search Results

1

Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement.

Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Schiffmann R, et al. Among authors: ries m. Virchows Arch. 2006 Mar;448(3):337-43. doi: 10.1007/s00428-005-0089-x. Epub 2005 Nov 29. Virchows Arch. 2006. PMID: 16315019 Free PMC article.

2

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.

Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Schiffmann R, et al. Among authors: ries m. Nephrol Dial Transplant. 2006 Feb;21(2):345-54. doi: 10.1093/ndt/gfi152. Epub 2005 Oct 4. Nephrol Dial Transplant. 2006. PMID: 16204287 Clinical Trial.

3

Fabry's disease--an important risk factor for stroke.

Schiffmann R, Ries M. Schiffmann R, et al. Among authors: ries m. Lancet. 2005 Nov 19;366(9499):1754-6. doi: 10.1016/S0140-6736(05)67636-2. Lancet. 2005. PMID: 16298202 No abstract available.

4

Enzyme replacement therapy and intraepidermal innervation density in Fabry disease.

Schiffmann R, Hauer P, Freeman B, Ries M, Scott LJ, Polydefkis M, Brady RO, McArthur JC, Wagner K. Schiffmann R, et al. Among authors: ries m. Muscle Nerve. 2006 Jul;34(1):53-6. doi: 10.1002/mus.20550. Muscle Nerve. 2006. PMID: 16583374 Clinical Trial.

5

Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, Ries M. Schiffmann R, et al. Among authors: ries m. J Am Soc Nephrol. 2007 May;18(5):1576-83. doi: 10.1681/ASN.2006111263. Epub 2007 Apr 4. J Am Soc Nephrol. 2007. PMID: 17409308 Free PMC article. Clinical Trial.

6

Fabry Disease: A Disorder of Childhood Onset.

Schiffmann R, Ries M. Schiffmann R, et al. Among authors: ries m. Pediatr Neurol. 2016 Nov;64:10-20. doi: 10.1016/j.pediatrneurol.2016.07.001. Epub 2016 Jul 29. Pediatr Neurol. 2016. PMID: 27555236 Review.

7

Pediatric Fabry disease.

Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R. Ries M, et al. Pediatrics. 2005 Mar;115(3):e344-55. doi: 10.1542/peds.2004-1678. Epub 2005 Feb 15. Pediatrics. 2005. PMID: 15713906

8

The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.

Gupta S, Ries M, Kotsopoulos S, Schiffmann R. Gupta S, et al. Among authors: ries m. Medicine (Baltimore). 2005 Sep;84(5):261-268. doi: 10.1097/01.md.0000178976.62537.6b. Medicine (Baltimore). 2005. PMID: 16148726 Free article.

9

Quantitative dysmorphology assessment in Fabry disease.

Ries M, Moore DF, Robinson CJ, Tifft CJ, Rosenbaum KN, Brady RO, Schiffmann R, Krasnewich D. Ries M, et al. Genet Med. 2006 Feb;8(2):96-101. doi: 10.1097/01.gim.0000200950.25118.dd. Genet Med. 2006. PMID: 16481892 Free article.

10

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R. Ries M, et al. Pediatrics. 2006 Sep;118(3):924-32. doi: 10.1542/peds.2005-2895. Pediatrics. 2006. PMID: 16950982 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

656 results

Search Page

Filters